【作者】 王瑱萍；

【导师】 罗坚真；

【作者基本信息】 江西医学院 ， 妇产科， 2003， 硕士

【摘要】 目的：探讨卵巢癌病变中P16抑癌基因的改变和可能的作用机制。方法：应用免疫组化和原位杂交技术检测40例卵巢上皮性癌，12例交界性肿瘤和16例良性肿瘤中的P16表达及其与临床病理的关系；并结合PCNA的改变，进一步了解P16基因在卵巢癌发生，发展过程中可能的病变机制。结果：①在卵巢恶性肿瘤，交界性肿瘤和良性肿瘤中P16蛋白表达阳性率分别为77.5%，41.67%和12.5%，强阳性率依次为65%，16.67%，0 (P<0.001)。P16表达强度与临床分期和生存期有显著相关性(P<0.05)，阳性表达多见于低分化，临床晚期和生存期短的卵巢癌患者。②低分化，临床晚期，生存期短病例组中的PCNA表达高于中﹑高分化，临床早期和生存期长的病例组。③P16和PCNA表达呈正向相关性。④年龄，淋巴结转移，PCNA表达是影响上皮性卵巢癌的预后因素。结论：P16蛋白高表达与卵巢癌进展相关。P16和PCNA的检测可作为判断卵巢癌恶性程度和预测预后的参考指标。更多还原

【Abstract】 Objective: To explore the alteration and the possible mechanism of tumor suppressor gene P16 in the progression of ovarian carcinoma. Methods: Using immunohistochemical and in situ hybridization techniques. The expression of P16, PCNA and their relationship with clinicopathological parameters were examined in 40 cases of ovarian epithelial cancers, 12 cases of borderline ovarian neoplasms and 16 cases of benign ovarian neoplasms. Results: ①The positive rates of P16 protein among the malignant, borderline and benign ovarian neoplasms were 77.5%, 41.67% and 12.5%. The strong positive rates were 65%, 16.67%, 0, respectively (P<0.001). The expressive rate and intensity of P16 were associated with clinical stages and survival time of patients (P<0.05). P16 protein was positive in most patients of G3, advanced stages or short survival time. ②The PCNA index in G2~G3, advanced stages or short survival time was higher than those in G1, early stages or long survival time. ③There was positive correlation between the expression of P16 and PCNA. ④Age, lymph node metastasis and expression of PCNA were the prognosis factors of ovarian carcinoma. Conclusions: The over-expression of P16 gene may be involved in ovarian epithelial cancer. The detection of P16, PCNA can evaluate the malignant degrees and may predict prognosis of ovarian carcinoma.更多还原